Dyne Therapeutics, Inc. (BX:DYN) Financings

Dyne Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Made bigger: US$375.15M · US$20.5 a share · Morgan Stanley +5
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), LifeSci Capital (co-lead), Raymond James (co-lead), Jones
Jul 22, 2026
Public offering of common stock
Closed: US$402.5M raised · US$18.44 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead)
Dec 11, 2025
Public offering of common stock
Closed: US$230M raised · US$8.25 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Jones
Jul 2, 2025
At-the-market programme of common stock
Closed: US$140.6M raised
Use of proceeds: To fund operations, together with existing cash, at least into the second half of 2026
Feb 27, 2025

Read by 6ix AI from the company's releases